[This corrects the article DOI: 10.3389/fmolb.2023.1082915.].
Keywords: ER+/HER2−; PIK3CA mutations; advanced breast cancer; molecular pathology; ring trial; validation.
Copyright © 2024 Peixoto, Cirnes, Carvalho, Andrade, Maria José Brito, Borralho, Coimbra, Borralho, Carneiro, Castro, Correia, Dionísio, Faria, Figueiredo, Gomes, Paixão, Pinheiro, Prazeres, Ribeiro, Salgueiro, Schmitt, Silva, Silvestre, Sousa, Almeida-Tavares, Teixeira, André and Machado.